<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711682</url>
  </required_header>
  <id_info>
    <org_study_id>07-2017</org_study_id>
    <nct_id>NCT03711682</nct_id>
  </id_info>
  <brief_title>Reducing Plasma Glucose Effect of Cinnamon in Type 2 Diabetic Patients in the Municipality of Comasagua</brief_title>
  <acronym>GCIG</acronym>
  <official_title>Hypoglycemic Effect of Cinnamomum Verum in Type 2 Diabetic Patients in the Municipality of Comasagua</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Dr. José Matías Delgado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Nacional Rosales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unidad Comunitaria de Salud Familiar Intermedia de Comasagua (UCSFI-Comasagua)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación Salvadoreña de Diabetes (ASADI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Dr. José Matías Delgado</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is evaluate the effect of cinnamon powder (Cinnamomum verum) on the
      glycaemia and HbA1c (Glycohemoglobin) of type 2 diabetic Salvadoran patients, whose
      hypoglycemic treatment is only Metformin. To carry out this objective, subjects who agree to
      be part of the study will subjected to measurements of their body weight, height, body mass
      index, waist circumference, systolic pressure, diastolic pressure, capillary glucose (with
      glucose meter) every 2 weeks, and their glycohemoglobin (HbA1c) at the beginning and at the
      end of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted for 12 weeks (3 months) with 30 participants diagnosed with type
      2 diabetes mellitus, whose only treatment for diabetes is metformin.

      Both, intervention with Cinnamon (Cinnamomum verum) and wheat flour (placebo) will be
      encapsulated in titanium white capsules with 500 mg of powder, that will take place in
      agro-industry laboratories, and will be packed in glass bottles with a content of 56 capsules
      and a bag of silica gel.

      The data of the probable participants will verified with their medical records in the
      Intermediate Communitarian Unit of Family Health of Comasagua municipality (UCSFI-Comasagua).
      Then those who meet the criteria will contacted to be enrolled in the study, if they agreed,
      an informed consent will signed or stamped if the participant cannot read and write.

      The randomization will be make using a list of the participants and them using the Graphpad
      QuickCalcs option of &quot;Randomly assign participants to groups&quot;, assigning the participants to
      a group A (intervention) or B (placebo).

      Participants in both groups will continue to receive the treatment they would normally
      receive from their respective primary care providers during the duration of the study.

      The participants, who accepted and signed the informed consent, will provided with a moth
      calendar with the schedule of the measures. The measured variables are body weight, height,
      body mass index, waist circumference, systolic pressure, diastolic pressure, capillary
      glucose (with glucose meter) and HbA1c. The measurements will take place every 2 weeks (week
      0, 2, 4, 6, 8, 10 and 12) with the exception of HbA1c which will be measured at the beginning
      and at the end of the study (week 0 and 12).

      The obtained data will be write in the paper medical records of each participant and then
      exported to a database in Microsoft Excel, after that data will processed in statistical
      software. In case of adverse effects, this will recorded into a formulary dedicated to it,
      this provided to the UCSFI-Comasagua physicians with the contact data of the researchers. In
      addition, to perform this study the researchers make an agreement with the UCSFI-Comasagua
      and with the endocrinology service of the Rosales National Hospital along with the Salvadoran
      Association of Diabetes (ASADI) to provide health care and support to those participants who
      presented adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">May 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Week 0 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Capillary Glucose</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic pressure</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Pressure</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Theoretical HbA1c</measure>
    <time_frame>Week 0, 4, 8, 12</time_frame>
    <description>Theoretical HbA1c, calculated using the mean of the capillary glucose of each month (every 4 weeks), and the formula A1c% = (AG mg/dL + 46.7) / 28.7</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cinnamon (Intervented)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wheat Flour (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cinnamon</intervention_name>
    <description>Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.</description>
    <arm_group_label>Cinnamon (Intervented)</arm_group_label>
    <other_name>Intervened</other_name>
    <other_name>Group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wheat Flour</intervention_name>
    <description>Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.</description>
    <arm_group_label>Wheat Flour (Placebo)</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Group B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Type 2 Diabetes mellitus.

          -  Treated only with Metformin as unique treatment for diabetes.

        Exclusion Criteria:

          -  Hypersensitivity or allergy reported to Cinnamomum spp. or Peruvian balm.

          -  Ulcer of gastrointestinal location.

          -  Chronic treatment with analgesics, antibiotics, estrogens, antineoplastics,
             antihypertensives of the beta-blocker type, anti-inflammatory, medications whose route
             of action is Gamma-Aminobutyric Acid and / or anticoagulants.

          -  Under treatment with steroid and / or aspirin.

          -  Subject that use alternative medicine treatments.

          -  Women of childbearing age who do not use any contraceptive method.

          -  Subjects subjected to surgical procedures in the 6 weeks prior to the beginning of the
             study.

          -  Subjects who presented fasting glycemia levels greater than 400 mg/dL in the previous
             control.

          -  Allergies to wheat and/or diagnosed with celiac disease.

          -  Adverse Drug Reaction during the study.

          -  Subjects whose treatment schedule changed during the study intervention.

          -  Subjects that does not accept to be part of the study, decides to leave the study or
             does not have adherence to the treatment provided.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Padilla, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Dr. José Matías Delgado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana E Centeno, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Dr. José Matías Delgado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melissa V Abarca, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Dr. José Matías Delgado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto W Cerritos, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de El Salvador, Hospital Nacional Rosales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William A Hoyos, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Dr. José Matías Delgado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karla M Navarrete, M.D., MPh.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Secretaría Antidrogas de la Ciudad de San Salvador</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad Comunitaria de Salud Familiar Intermedia de Comasagua (UCSFI-Comasagua)</name>
      <address>
        <city>Comasagua</city>
        <state>La Libertad</state>
        <zip>0504</zip>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>El Salvador</country>
  </location_countries>
  <link>
    <url>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.20.77</url>
    <description>FDA - Substances Generally Recognized as Safe, Cinnamon bark, Ceylon.</description>
  </link>
  <link>
    <url>https://www.fda.gov/iceci/compliancemanuals/compliancepolicyguidancemanual/ucm074468.htm</url>
    <description>FDA - Compliance Policy Guides (CPGs), CPG Sec. 525.750 Spices - Definitions, 10. Cinnamon</description>
  </link>
  <link>
    <url>http://www.diabetesatlas.org/</url>
    <description>Diabetes Atlas, International Federation of Diabetes</description>
  </link>
  <link>
    <url>http://apps.who.int/iris/bitstream/10665/254649/1/9789243565255-spa.pdf</url>
    <description>World Health Organization. World report on diabetes 2016</description>
  </link>
  <link>
    <url>http://www.administracion.usmp.edu.pe/institutoconsumo/wp-content/uploads/LIBRO-II-CONSENSO-LATINOAMERICANO-DE-OBESIDAD-2017.pdf</url>
    <description>II Latin American Consensus on Obesity. Latin American Federation of Obesity Societies</description>
  </link>
  <link>
    <url>http://www.digestyc.gob.sv/index.php/temas/des/ehpm/publicaciones-ehpm.html?download=488%3Aestimaciones-y-proyecciones-de-poblacion</url>
    <description>Estimates and Projections of National Population 2005-2050, Departmental 2005-2025. El Salvador.</description>
  </link>
  <link>
    <url>http://www.who.int/diabetes/country-profiles/slv_es.pdf?ua=1.</url>
    <description>World Health Organization. Country profiles for diabetes 2016, El Salvador.</description>
  </link>
  <link>
    <url>https://www.salud.gob.sv/archivos/comunicaciones/archivos_comunicados2017/pdf/presentaciones_evento20032017/01-ENECA-ELS-2015.pdf</url>
    <description>National Survey of chronic noncommunicable diseases in the adult population of El Salvador.</description>
  </link>
  <link>
    <url>http://www.salud.gob.sv/download/informe-de-labores-2015-2016/</url>
    <description>Work report 2015-2016. Ministry of Health of El Salvador.</description>
  </link>
  <reference>
    <citation>Medagama AB. The glycaemic outcomes of Cinnamon, a review of the experimental evidence and clinical trials. Nutr J. 2015 Oct 16;14:108. doi: 10.1186/s12937-015-0098-9. Review.</citation>
    <PMID>26475130</PMID>
  </reference>
  <reference>
    <citation>Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004 May;27(5):1218-24. Review.</citation>
    <PMID>15111553</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan;31 Suppl 1:S61-78. doi: 10.2337/dc08-S061. Erratum in: Diabetes Care. 2010 Aug;33(8):1911.</citation>
    <PMID>18165339</PMID>
  </reference>
  <reference>
    <citation>Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003 Apr;26(4):1277-94. Review.</citation>
    <PMID>12663610</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015 Jan;38 Suppl:S8-S16. doi: 10.2337/dc15-S005. Review.</citation>
    <PMID>25537714</PMID>
  </reference>
  <reference>
    <citation>Ros Pérez M, Medina-Gómez G. [Obesity, adipogenesis and insulin resistance]. Endocrinol Nutr. 2011 Aug-Sep;58(7):360-9. doi: 10.1016/j.endonu.2011.05.008. Epub 2011 Jul 22. Review. Spanish.</citation>
    <PMID>21778123</PMID>
  </reference>
  <reference>
    <citation>Canivell S, Gomis R. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmun Rev. 2014 Apr-May;13(4-5):403-7. doi: 10.1016/j.autrev.2014.01.020. Epub 2014 Jan 11. Review.</citation>
    <PMID>24424179</PMID>
  </reference>
  <reference>
    <citation>Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G, Ng DP, Holmkvist J, Borch-Johnsen K, Jørgensen T, Sandbaek A, Lauritzen T, Hansen T, Nurbaya S, Tsunoda T, Kubo M, Babazono T, Hirose H, Hayashi M, Iwamoto Y, Kashiwagi A, Kaku K, Kawamori R, Tai ES, Pedersen O, Kamatani N, Kadowaki T, Kikkawa R, Nakamura Y, Maeda S. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet. 2008 Sep;40(9):1098-102. doi: 10.1038/ng.208.</citation>
    <PMID>18711366</PMID>
  </reference>
  <reference>
    <citation>Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nat Rev Endocrinol. 2011 Nov 8;8(4):228-36. doi: 10.1038/nrendo.2011.183. Review.</citation>
    <PMID>22064493</PMID>
  </reference>
  <reference>
    <citation>Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013 Mar;7(1):14-24. doi: 10.1007/s11684-013-0262-6. Epub 2013 Mar 9. Review.</citation>
    <PMID>23471659</PMID>
  </reference>
  <reference>
    <citation>Sacks DB. Measurement of hemoglobin A(1c): a new twist on the path to harmony. Diabetes Care. 2012 Dec;35(12):2674-80. doi: 10.2337/dc12-1348. Review.</citation>
    <PMID>23173136</PMID>
  </reference>
  <reference>
    <citation>Sacks DB. Correlation between hemoglobin A1c (HbA1c) and average blood glucose: can HbA1c be reported as estimated blood glucose concentration? J Diabetes Sci Technol. 2007 Nov;1(6):801-3.</citation>
    <PMID>19885151</PMID>
  </reference>
  <reference>
    <citation>Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012 Jul;16(4):528-31. doi: 10.4103/2230-8210.98004.</citation>
    <PMID>22837911</PMID>
  </reference>
  <reference>
    <citation>Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015 Oct 29;373(18):1720-32. doi: 10.1056/NEJMoa1504347.</citation>
    <PMID>26510021</PMID>
  </reference>
  <reference>
    <citation>Guthrie RA, Guthrie DW. Pathophysiology of diabetes mellitus. Crit Care Nurs Q. 2004 Apr-Jun;27(2):113-25. Review.</citation>
    <PMID>15137354</PMID>
  </reference>
  <reference>
    <citation>Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013 Feb 14;152(4):673-84. doi: 10.1016/j.cell.2013.01.041.</citation>
    <PMID>23415219</PMID>
  </reference>
  <reference>
    <citation>Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001 Dec 13;414(6865):799-806.</citation>
    <PMID>11742412</PMID>
  </reference>
  <reference>
    <citation>Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000 Jul;106(2):165-9. Review.</citation>
    <PMID>10903329</PMID>
  </reference>
  <reference>
    <citation>Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008 Aug;31(8):1473-8. doi: 10.2337/dc08-0545. Epub 2008 Jun 7. Erratum in: Diabetes Care. 2009 Jan;32(1):207.</citation>
    <PMID>18540046</PMID>
  </reference>
  <reference>
    <citation>van 't Riet E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, Dekker JM. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care. 2010 Jan;33(1):61-6. doi: 10.2337/dc09-0677. Epub 2009 Oct 6.</citation>
    <PMID>19808928</PMID>
  </reference>
  <reference>
    <citation>Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001 Dec;24(12):2023-9.</citation>
    <PMID>11723077</PMID>
  </reference>
  <reference>
    <citation>Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002 Feb;25(2):275-8.</citation>
    <PMID>11815495</PMID>
  </reference>
  <reference>
    <citation>B. K. M. Goud, B. Nayal, O. S. Devi, T. G. Sathisha, S. Shivashanker and R. N. Devaki. Relation of calculated HbA1C with fasting plasma glucose and duration of diabetes. International Journal of Applied Biology and Pharmaceutical Technology. 2011;2(2):58-61.</citation>
  </reference>
  <reference>
    <citation>Dugoua JJ, Seely D, Perri D, Cooley K, Forelli T, Mills E, Koren G. From type 2 diabetes to antioxidant activity: a systematic review of the safety and efficacy of common and cassia cinnamon bark. Can J Physiol Pharmacol. 2007 Sep;85(9):837-47. Review.</citation>
    <PMID>18066129</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo C, Ceschi A, Kupferschmidt H, Lüde S, De Souza Nascimento E, Dos Santos A, Colombo F, Frigerio G, Nørby K, Plumb J, Finglas P, Restani P. Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. Br J Clin Pharmacol. 2015 Apr;79(4):578-92. doi: 10.1111/bcp.12519. Review.</citation>
    <PMID>25251944</PMID>
  </reference>
  <reference>
    <citation>Ulbricht C, Seamon E, Windsor RC, Armbruester N, Bryan JK, Costa D, Giese N, Gruenwald J, Iovin R, Isaac R, Serrano JM, Tanguay-Colucci S, Weissner W, Yoon H, Zhang J. An evidence-based systematic review of cinnamon (Cinnamomum spp.) by the Natural Standard Research Collaboration. J Diet Suppl. 2011 Dec;8(4):378-454. doi: 10.3109/19390211.2011.627783. Review.</citation>
    <PMID>22432776</PMID>
  </reference>
  <reference>
    <citation>Sahib AS. Anti-diabetic and antioxidant effect of cinnamon in poorly controlled type-2 diabetic Iraqi patients: A randomized, placebo-controlled clinical trial. J Intercult Ethnopharmacol. 2016 Feb 21;5(2):108-13. doi: 10.5455/jice.20160217044511. eCollection 2016 Mar-Apr.</citation>
    <PMID>27104030</PMID>
  </reference>
  <reference>
    <citation>N. G. Vailianou, A. Evangelopoulos, A. Kolia and C. Kazazis. Hypoglycemic and hipolipidemic effects of cinnamon. Current Topics in Nutraceutical Research. 2014;12(4):127-34</citation>
  </reference>
  <reference>
    <citation>Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996 Jan;137(1):354-66.</citation>
    <PMID>8536636</PMID>
  </reference>
  <reference>
    <citation>Sheng X, Zhang Y, Gong Z, Huang C, Zang YQ. Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors. PPAR Res. 2008;2008:581348. doi: 10.1155/2008/581348. Epub 2008 Dec 11.</citation>
    <PMID>19096709</PMID>
  </reference>
  <reference>
    <citation>Rao PV, Gan SH. Cinnamon: a multifaceted medicinal plant. Evid Based Complement Alternat Med. 2014;2014:642942. doi: 10.1155/2014/642942. Epub 2014 Apr 10. Review.</citation>
    <PMID>24817901</PMID>
  </reference>
  <reference>
    <citation>Cao H, Polansky MM, Anderson RA. Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes. Arch Biochem Biophys. 2007 Mar 15;459(2):214-22. Epub 2007 Jan 25.</citation>
    <PMID>17316549</PMID>
  </reference>
  <reference>
    <citation>Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003 Dec;26(12):3215-8.</citation>
    <PMID>14633804</PMID>
  </reference>
  <reference>
    <citation>Blevins SM, Leyva MJ, Brown J, Wright J, Scofield RH, Aston CE. Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2236-7. Epub 2007 Jun 11.</citation>
    <PMID>17563345</PMID>
  </reference>
  <reference>
    <citation>Anderson RA, Zhan Z, Luo R, Guo X, Guo Q, Zhou J, Kong J, Davis PA, Stoecker BJ. Cinnamon extract lowers glucose, insulin and cholesterol in people with elevated serum glucose. J Tradit Complement Med. 2015 Apr 18;6(4):332-336. eCollection 2016 Oct.</citation>
    <PMID>27774415</PMID>
  </reference>
  <reference>
    <citation>Lu T, Sheng H, Wu J, Cheng Y, Zhu J, Chen Y. Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes. Nutr Res. 2012 Jun;32(6):408-12. doi: 10.1016/j.nutres.2012.05.003. Epub 2012 Jun 14.</citation>
    <PMID>22749176</PMID>
  </reference>
  <reference>
    <citation>Hlebowicz J, Hlebowicz A, Lindstedt S, Björgell O, Höglund P, Holst JJ, Darwiche G, Almér LO. Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects. Am J Clin Nutr. 2009 Mar;89(3):815-21. doi: 10.3945/ajcn.2008.26807. Epub 2009 Jan 21.</citation>
    <PMID>19158209</PMID>
  </reference>
  <reference>
    <citation>R. A. Anderson. Cinnamon and Glucose Homeostasis. Nutrition Today. 2014;49(Supplement):S10-S1.</citation>
  </reference>
  <reference>
    <citation>E. E.-D. Gaber. Antidiabetic and hypolipidemic effects of Ceylon cinnamon (Cinnamomum verum) in alloxan-diabetic rats. Journal of Medicinal Plants Research 6(9): 1685-91, 2012.</citation>
  </reference>
  <reference>
    <citation>Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann Fam Med. 2013 Sep-Oct;11(5):452-9. doi: 10.1370/afm.1517. Review.</citation>
    <PMID>24019277</PMID>
  </reference>
  <reference>
    <citation>A. S. Alanazi, M. U. Khan. Cinnamon use in type 2 diabetes an updated meta analysis. World Journal of Pharmacy and Pharmaceutical Sciences 4(05):1838-52, 2015.</citation>
  </reference>
  <reference>
    <citation>Costello RB, Dwyer JT, Saldanha L, Bailey RL, Merkel J, Wambogo E. Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review. J Acad Nutr Diet. 2016 Nov;116(11):1794-1802. doi: 10.1016/j.jand.2016.07.015. Epub 2016 Sep 8. Review.</citation>
    <PMID>27618575</PMID>
  </reference>
  <reference>
    <citation>Leach MJ, Kumar S. Cinnamon for diabetes mellitus. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD007170. doi: 10.1002/14651858.CD007170.pub2. Review.</citation>
    <PMID>22972104</PMID>
  </reference>
  <reference>
    <citation>Baker WL, Gutierrez-Williams G, White CM, Kluger J, Coleman CI. Effect of cinnamon on glucose control and lipid parameters. Diabetes Care. 2008 Jan;31(1):41-3. Epub 2007 Oct 1.</citation>
    <PMID>17909085</PMID>
  </reference>
  <reference>
    <citation>M. L. Casas Oñate and D. Montoya Martínez. ¿Son fiables los medidores de glucemia capilar?. Avances en Diabetología 28(5):110-3, 2012.</citation>
  </reference>
  <reference>
    <citation>I. Yépez, R. García and T. Toledo. Complicaciones agudas: Crisis hiperglucémica. Revista Venezolana de Endocrinología y Metabolismo 10:75-83, 2012.</citation>
  </reference>
  <reference>
    <citation>Pariente Rodrigo E, Deib-Morgan K, García de Diego O, García-Velasco P, Sgaramella GA, García González I. [Accuracy and reliability between glucose meters: A study under normal clinical practice conditions]. Semergen. 2017 Jan - Feb;43(1):20-27. doi: 10.1016/j.semerg.2016.01.011. Epub 2016 Mar 8. Spanish.</citation>
    <PMID>26968861</PMID>
  </reference>
  <reference>
    <citation>Dijkstra R, Braspenning J, Grol R. Empowering patients: how to implement a diabetes passport in hospital care. Patient Educ Couns. 2002 Jun;47(2):173-7.</citation>
    <PMID>12191541</PMID>
  </reference>
  <reference>
    <citation>Azizi A, Aboutorabi R, Mazloum-Khorasani Z, Hoseini B, Tara M. Diabetic Personal Health Record: A Systematic Review Article. Iran J Public Health. 2016 Nov;45(11):1388-1398. Review.</citation>
    <PMID>28032056</PMID>
  </reference>
  <reference>
    <citation>R. D. Cervantes-Villagrana and J. M. Presno-Bernal. Fisiopatología de la diabetes y los mecanismos de muerte de las células β pancreáticas. Revista de Endocrinología y Nutrición 21(3):98-106, 2013.</citation>
  </reference>
  <results_reference>
    <citation>American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64. doi: 10.2337/dc18-S006. Review.</citation>
    <PMID>29222377</PMID>
  </results_reference>
  <results_reference>
    <citation>Talaei B, Amouzegar A, Sahranavard S, Hedayati M, Mirmiran P, Azizi F. Effects of Cinnamon Consumption on Glycemic Indicators, Advanced Glycation End Products, and Antioxidant Status in Type 2 Diabetic Patients. Nutrients. 2017 Sep 8;9(9). pii: E991. doi: 10.3390/nu9090991.</citation>
    <PMID>28885566</PMID>
  </results_reference>
  <results_reference>
    <citation>Sami W, Ansari T, Butt NS, Hamid MRA. Effect of diet on type 2 diabetes mellitus: A review. Int J Health Sci (Qassim). 2017 Apr-Jun;11(2):65-71. Review.</citation>
    <PMID>28539866</PMID>
  </results_reference>
  <results_reference>
    <citation>Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, Dallosso HM, Daly H, Doherty Y, Eaton S, Fox C, Oliver L, Rantell K, Rayman G, Khunti K; Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008 Mar 1;336(7642):491-5. doi: 10.1136/bmj.39474.922025.BE. Epub 2008 Feb 14. Erratum in: BMJ. 2008 Apr 19;336(7649):doi:10.1136/bmj.39553.528299.AD.</citation>
    <PMID>18276664</PMID>
  </results_reference>
  <results_reference>
    <citation>Zare R, Nadjarzadeh A, Zarshenas MM, Shams M, Heydari M. Efficacy of cinnamon in patients with type II diabetes mellitus: A randomized controlled clinical trial. Clin Nutr. 2019 Apr;38(2):549-556. doi: 10.1016/j.clnu.2018.03.003. Epub 2018 Mar 11.</citation>
    <PMID>29605574</PMID>
  </results_reference>
  <results_reference>
    <citation>Azimi P, Ghiasvand R, Feizi A, Hosseinzadeh J, Bahreynian M, Hariri M, Khosravi-Boroujeni H. Effect of cinnamon, cardamom, saffron and ginger consumption on blood pressure and a marker of endothelial function in patients with type 2 diabetes mellitus: A randomized controlled clinical trial. Blood Press. 2016 Jun;25(3):133-40. doi: 10.3109/08037051.2015.1111020. Epub 2016 Jan 12.</citation>
    <PMID>26758574</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahmoodnia L, Aghadavod E, Rafieian-Kopaei M. Ameliorative impact of cinnamon against high blood pressure; an updated review. Journal of Renal Injury Prevention 6(3):171-6, 2017.</citation>
  </results_reference>
  <results_reference>
    <citation>Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care. 2014 Apr;37(4):1048-51. doi: 10.2337/dc13-2173. Epub 2014 Feb 10.</citation>
    <PMID>24513588</PMID>
  </results_reference>
  <results_reference>
    <citation>Klonoff DC. ADAG study group data links A1C levels with empirically measured blood glucose values - new treatment guidelines will now be needed. J Diabetes Sci Technol. 2014 May;8(3):439-43. doi: 10.1177/1932296814529638. Epub 2014 Apr 30.</citation>
    <PMID>24876603</PMID>
  </results_reference>
  <results_reference>
    <citation>Feller S, Boeing H, Pischon T. Body mass index, waist circumference, and the risk of type 2 diabetes mellitus: implications for routine clinical practice. Dtsch Arztebl Int. 2010 Jul;107(26):470-6. doi: 10.3238/arztebl.2010.0470. Epub 2010 Jul 2.</citation>
    <PMID>20644701</PMID>
  </results_reference>
  <results_reference>
    <citation>Funnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, Maryniuk M, Peyrot M, Piette JD, Reader D, Siminerio LM, Weinger K, Weiss MA. National standards for diabetes self-management education. Diabetes Care. 2010 Jan;33 Suppl 1:S89-96. doi: 10.2337/dc10-S089. Review.</citation>
    <PMID>20042780</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Dr. José Matías Delgado</investigator_affiliation>
    <investigator_full_name>Miguel Antonio Padilla Pimentel, MD</investigator_full_name>
    <investigator_title>Doctor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Glucose</keyword>
  <keyword>Cinnamomum verum</keyword>
  <keyword>Cinnamomum zeylanicum</keyword>
  <keyword>Cinnamon</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Glycated Hemoglobin</keyword>
  <keyword>Diastolic Pressure</keyword>
  <keyword>Systolic Pressure</keyword>
  <keyword>Body Mass Index</keyword>
  <keyword>BMI</keyword>
  <keyword>Metformin</keyword>
  <keyword>Waist Circumference</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There's not Individual Patient Data sharing plan because at the moment the participants signed the informed consent it stipulate their individual data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

